BIIB·Biogen Inc.

Representative Gilbert Ray Cisneros, Jr. purchased shares of Biogen on January 30th, which may signal insider confidence in the company. Mizuho raised its price target for BIIB to $236, maintaining an Outperform rating, reflecting a positive outlook on the company's prospects. Wedbush also increased its price target for BIIB to $187, citing Biogen's Q4 and full-year financial results. However, StockStory's analysis suggests Biogen faces significant headwinds, citing declining sales and profitability. Biogen's Q4 earnings exceeded expectations, driven by strong performance from newer products like Lekembi and VUMERITY. The company is also focusing on growth products, with management expressing confidence in its operational execution. Biogen highlighted its lupus pipeline at a Piper Sandler symposium, focusing on litifilimab and dapirolizumab. The FDA granted Breakthrough Therapy Designation for litifilimab in cutaneous lupus erythematosus, and positive trial results were reported for high-dose nusinersen in spinal muscular atrophy. Biogen's board is undergoing a leadership transition, with Dr. Maria C. Freire taking over as chair from Caroline Dorsa after the 2026 annual meeting.